NasdaqGS - Delayed Quote USD
Generation Bio Co. (GBIO)
At close: November 1 at 4:00 PM EDT
After hours: November 1 at 4:03 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
13,174.0000
5,904.0000
--
--
--
Operating Expense
125,468.0000
144,467.0000
141,182.0000
119,101.0000
81,114.0000
Operating Income
-112,294.0000
-138,563.0000
-141,182.0000
-119,101.0000
-81,114.0000
Net Non Operating Interest Income Expense
12,296.0000
11,951.0000
4,543.0000
-50.0000
591.0000
Pretax Income
-158,425.0000
-126,612.0000
-136,639.0000
-119,151.0000
-80,523.0000
Net Income Common Stockholders
-158,425.0000
-126,612.0000
-136,639.0000
-119,151.0000
-80,523.0000
Diluted NI Available to Com Stockholders
-158,425.0000
-126,612.0000
-136,639.0000
-119,151.0000
-80,523.0000
Basic EPS
-2.39
-1.96
-2.35
-2.12
-2.95
Diluted EPS
-2.39
-1.96
-2.35
-2.12
-2.95
Basic Average Shares
66,245.9020
64,483.5200
58,114.8930
56,295.4090
27,256.4940
Diluted Average Shares
66,245.9020
64,483.5200
58,114.8930
56,295.4090
27,256.4940
Total Operating Income as Reported
-170,721.0000
-138,563.0000
-141,182.0000
-119,101.0000
-81,114.0000
Total Expenses
125,468.0000
144,467.0000
141,182.0000
119,101.0000
81,114.0000
Net Income from Continuing & Discontinued Operation
-158,425.0000
-126,612.0000
-136,639.0000
-119,151.0000
-80,523.0000
Normalized Income
-99,998.0000
-126,612.0000
-136,639.0000
-119,151.0000
-80,523.0000
Interest Income
12,296.0000
11,951.0000
4,543.0000
--
--
Interest Expense
--
--
--
50.0000
--
Net Interest Income
12,296.0000
11,951.0000
4,543.0000
-50.0000
591.0000
EBIT
-112,294.0000
-138,563.0000
-141,182.0000
-119,101.0000
-81,114.0000
EBITDA
-107,101.0000
-133,300.0000
-136,052.0000
-114,569.0000
-77,682.0000
Reconciled Depreciation
5,193.0000
5,263.0000
5,130.0000
4,532.0000
3,432.0000
Net Income from Continuing Operation Net Minority Interest
-158,425.0000
-126,612.0000
-136,639.0000
-119,151.0000
-80,523.0000
Total Unusual Items Excluding Goodwill
-58,427.0000
--
--
--
--
Total Unusual Items
-58,427.0000
--
--
--
--
Normalized EBITDA
-48,674.0000
-133,300.0000
-136,052.0000
-114,569.0000
-77,682.0000
12/31/2020 - 6/12/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PMVP PMV Pharmaceuticals, Inc.
1.6300
0.00%
PASG Passage Bio, Inc.
0.6294
+2.34%
BRNS Barinthus Biotherapeutics plc
1.4320
-4.53%
STOK Stoke Therapeutics, Inc.
12.86
+4.05%
DSGN Design Therapeutics, Inc.
5.20
-0.76%
FDMT 4D Molecular Therapeutics, Inc.
8.10
+1.06%
FHTX Foghorn Therapeutics Inc.
8.30
+8.92%
ALXO ALX Oncology Holdings Inc.
1.4500
+1.40%
RLYB Rallybio Corporation
1.0100
-1.94%
ITOS iTeos Therapeutics, Inc.
8.81
+4.26%